Guideline Video

Guideline Resources

  • Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings
  • American College of Physicians
  • June 16, 2026
  • Summary
  • Full-text

Video Transcription

Just published June 16th, 2026, the American College of Physicians’s newest guideline on Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings.

The guideline is for internal medicine physicians and other clinicians caring in outpatient settings for adults with overweight or obesity.

In today’s rapid update, we’ll just be going over a summary of recommendations so for the full guideline, make sure to check it out on guidelinecentral.com

Let’s get started. 

  • The guideline suggests initiating one of the following pharmacologic treatments with lifestyle modifications for weight management in nonpregnant adults with obesity in outpatient settings:
    • First-line treatments are semaglutide and tirzepatide; 
    • second-line treatment is phentermine–topiramate; 
    • third-line treatment is liraglutide; 
    • fourth-line treatment is naltrexone–bupropion.
  • The guideline suggests initiating one of the following pharmacologic treatments with lifestyle modifications for weight management in nonpregnant adults with overweight and type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease:
    • First-line treatments are semaglutide and tirzepatide; 
    • second-line treatment is liraglutide.

And there you have it. Make sure to check out the full guideline from the American College of Physicians and other related clinical decision support tools at guidelinecentral.com.

Sign up for alerts and stay informed on the latest published articles and guidelines.